Ciapini Gianluca, Simonettii Matteo, Giuntoli Michele, Varchetta Giorgio, De Franco Silvia, Ipponi Edoardo, Scaglione Michelangelo, Parchi Paolo Domenico
Department of Orthopedics and Trauma Surgery, University of Pisa, Pisa 56124, Italy.
Adv Orthop. 2023 Mar 10;2023:1868943. doi: 10.1155/2023/1868943. eCollection 2023.
Knee osteoarthritis is a common disease with increasing incidence and prevalence in western countries. It can cause severe pain and functional limitations, thereby representing a threat for patients' quality of life and a burden for national health systems. Intra-articular injections with hyaluronic acid (HA) and platelet-rich plasma (PRP) have been used for decades in order to reduce the symptoms caused by osteoarthritis. In recent years, a combination of HA and PRP has been introduced in clinical practice with the aim to minimize the clinical presentation of osteoarthritis and potentially delay articular degeneration.
Sixty cases with grade II-III knee osteoarthritis according to the Kellgren-Lawrence classification were included in a prospective study, focused on the evaluation of clinical and functional outcomes after intra-articular knee injections. Cases were randomly divided into three groups. Twenty cases (Group ) were injected with HA, 20 (Group ) had PRP, and the remaining 20 (Group ) received a combination of HA and PRP. Basal WOMAC score and VAS score were recorded before the treatment and repeated within 3 and 6 months after the treatment.
At 6-month follow-up, Group (PRP + HA) was the one with the lowest WOMAC and VAS mean values. It was also the only group that reported a reduction in the two values both in the first three months and in the following three months. No major complication was recorded.
The combination of platelet-rich plasma and hyaluronic acid can be effective in the treatment of grade II-III knee osteoarthritis in a short-to-mid-term scenario. It represents an innovative and valuable alternative to the administration of its two components alone.
膝关节骨关节炎是一种常见疾病,在西方国家其发病率和患病率呈上升趋势。它可导致严重疼痛和功能受限,从而对患者的生活质量构成威胁,并给国家卫生系统带来负担。关节内注射透明质酸(HA)和富血小板血浆(PRP)已应用数十年,以减轻骨关节炎引起的症状。近年来,HA和PRP的联合应用已引入临床实践,旨在最大程度减轻骨关节炎的临床表现并可能延缓关节退变。
根据Kellgren-Lawrence分类法,纳入60例II-III级膝关节骨关节炎患者进行一项前瞻性研究,重点评估膝关节腔内注射后的临床和功能结局。将病例随机分为三组。20例(组)注射HA,20例(组)注射PRP,其余20例(组)接受HA和PRP联合注射。在治疗前记录基础WOMAC评分和VAS评分,并在治疗后3个月和6个月重复记录。
在6个月随访时,组(PRP + HA)的WOMAC和VAS平均值最低。它也是唯一在前三个月和后三个月这两个值均有所降低的组。未记录到重大并发症。
富血小板血浆和透明质酸联合应用在治疗II-III级膝关节骨关节炎的短期至中期情况下可能有效。它是单独使用其两种成分的一种创新且有价值的替代方法。